Working… Menu

A Neurokinin-1 Receptor Antagonist for the Treatment of Pruritus in Patients With Epidermolysis Bullosa

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03836001
Recruitment Status : Recruiting
First Posted : February 11, 2019
Last Update Posted : May 16, 2019
Epidermolysis Bullosa Research Partnership
Menlo Therapeutics
Information provided by (Responsible Party):
Albert Chiou, Stanford University

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : September 30, 2021
Estimated Study Completion Date : March 28, 2022